{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:21:54Z","timestamp":1786980114875,"version":"build-2736575974"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T00:00:00Z","timestamp":1656460800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T00:00:00Z","timestamp":1656460800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100010846","name":"Health and Family Planning Commission of Hubei Province","doi-asserted-by":"publisher","award":["WJ2019H060"],"award-info":[{"award-number":["WJ2019H060"]}],"id":[{"id":"10.13039\/501100010846","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Science, Technology and Innovation Seed Fund of Zhongnan Hospital of Wuhan University","award":["znpy2018123"],"award-info":[{"award-number":["znpy2018123"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Arch Otorhinolaryngol"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1007\/s00405-022-07435-2","type":"journal-article","created":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T09:04:32Z","timestamp":1656493472000},"page":"5057-5069","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Optimal induction chemotherapy regimen for locoregionally advanced nasopharyngeal carcinoma: an update Bayesian network meta-analysis"],"prefix":"10.1007","volume":"279","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4655-3108","authenticated-orcid":false,"given":"Qiuji","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaojie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yahua","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,29]]},"reference":[{"issue":"3","key":"7435_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H et al (2021) Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"7435_CR2","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3322\/caac.21338","volume":"66","author":"W Chen","year":"2016","unstructured":"Chen W et al (2016) Cancer statistics in China, 2015. CA Cancer J Clin 66(2):115\u2013132. https:\/\/doi.org\/10.3322\/caac.21338","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"7435_CR3","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1002\/cncr.29795","volume":"122","author":"JJ Pan","year":"2016","unstructured":"Pan JJ et al (2016) Proposal for the 8th edition of the AJCC\/UICC staging system for nasopharyngeal cancer in the era of intensity-modulated radiotherapy. Cancer 122(4):546\u2013558. https:\/\/doi.org\/10.1002\/cncr.29795","journal-title":"Cancer"},{"issue":"7","key":"7435_CR4","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1200\/JCO.20.03237","volume":"39","author":"YP Chen","year":"2021","unstructured":"Chen YP et al (2021) Chemotherapy in combination with radiotherapy for definitive-intent treatment of stage II\u2013IVA nasopharyngeal carcinoma: CSCO and ASCO Guideline. J Clin Oncol 39(7):840\u2013859. https:\/\/doi.org\/10.1200\/JCO.20.03237","journal-title":"J Clin Oncol"},{"key":"7435_CR5","doi-asserted-by":"publisher","first-page":"591205","DOI":"10.3389\/fonc.2020.591205","volume":"10","author":"SS Yang","year":"2020","unstructured":"Yang SS et al (2020) Effect of induction chemotherapy in nasopharyngeal carcinoma: an updated meta-analysis. Front Oncol 10:591205. https:\/\/doi.org\/10.3389\/fonc.2020.591205","journal-title":"Front Oncol"},{"issue":"8","key":"7435_CR6","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1158\/1078-0432.CCR-17-2656","volume":"24","author":"YP Chen","year":"2018","unstructured":"Chen YP et al (2018) Induction chemotherapy plus concurrent chemoradiotherapy in endemic nasopharyngeal carcinoma: individual patient data pooled analysis of four randomized trials. Clin Cancer Res 24(8):1824\u20131833. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-2656","journal-title":"Clin Cancer Res"},{"issue":"5","key":"7435_CR7","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1007\/s00405-020-06218-x","volume":"278","author":"M Tang","year":"2021","unstructured":"Tang M, Jia Z, Zhang J (2021) The evaluation of adding induction chemotherapy to concurrent chemoradiotherapy for locally advanced nasopharyngeal carcinoma: a meta-analysis. Eur Arch Otorhinolaryngol 278(5):1545\u20131558. https:\/\/doi.org\/10.1007\/s00405-020-06218-x","journal-title":"Eur Arch Otorhinolaryngol"},{"issue":"1","key":"7435_CR8","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1002\/ijc.32099","volume":"145","author":"WF Li","year":"2019","unstructured":"Li WF et al (2019) Concurrent chemoradiotherapy with\/without induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: long-term results of phase 3 randomized controlled trial. Int J Cancer 145(1):295\u2013305. https:\/\/doi.org\/10.1002\/ijc.32099","journal-title":"Int J Cancer"},{"issue":"11","key":"7435_CR9","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1016\/S1470-2045(16)30410-7","volume":"17","author":"Y Sun","year":"2016","unstructured":"Sun Y et al (2016) Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial. Lancet Oncol 17(11):1509\u20131520. https:\/\/doi.org\/10.1016\/S1470-2045(16)30410-7","journal-title":"Lancet Oncol"},{"issue":"12","key":"7435_CR10","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1056\/NEJMoa1905287","volume":"381","author":"Y Zhang","year":"2019","unstructured":"Zhang Y et al (2019) Gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma. N Engl J Med 381(12):1124\u20131135. https:\/\/doi.org\/10.1056\/NEJMoa1905287","journal-title":"N Engl J Med"},{"issue":"2","key":"7435_CR11","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1200\/JCO.2008.18.1545","volume":"27","author":"EP Hui","year":"2009","unstructured":"Hui EP et al (2009) Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma. J Clin Oncol 27(2):242\u2013249. https:\/\/doi.org\/10.1200\/JCO.2008.18.1545","journal-title":"J Clin Oncol"},{"key":"7435_CR12","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.ejca.2016.12.039","volume":"75","author":"SM Cao","year":"2017","unstructured":"Cao SM et al (2017) Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase III multicentre randomised controlled trial. Eur J Cancer 75:14\u201323. https:\/\/doi.org\/10.1016\/j.ejca.2016.12.039","journal-title":"Eur J Cancer"},{"issue":"9","key":"7435_CR13","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1093\/annonc\/mdy249","volume":"29","author":"RL Hong","year":"2018","unstructured":"Hong RL et al (2018) Final results of a randomized phase III trial of induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in patients with stage IVA and IVB nasopharyngeal carcinoma-Taiwan Cooperative Oncology Group (TCOG) 1303 Study. Ann Oncol 29(9):1972\u20131979. https:\/\/doi.org\/10.1093\/annonc\/mdy249","journal-title":"Ann Oncol"},{"issue":"1","key":"7435_CR14","doi-asserted-by":"publisher","first-page":"943","DOI":"10.18549\/PharmPract.2017.01.943","volume":"15","author":"FS Tonin","year":"2017","unstructured":"Tonin FS et al (2017) Network meta-analysis: a technique to gather evidence from direct and indirect comparisons. Pharm Pract (Granada) 15(1):943. https:\/\/doi.org\/10.18549\/PharmPract.2017.01.943","journal-title":"Pharm Pract (Granada)"},{"issue":"11","key":"7435_CR15","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1007\/s00296-014-2994-2","volume":"34","author":"F Catala-Lopez","year":"2014","unstructured":"Catala-Lopez F et al (2014) Network meta-analysis for comparing treatment effects of multiple interventions: an introduction. Rheumatol Int 34(11):1489\u20131496. https:\/\/doi.org\/10.1007\/s00296-014-2994-2","journal-title":"Rheumatol Int"},{"key":"7435_CR16","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP et al (2011) The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ 343:d5928. https:\/\/doi.org\/10.1136\/bmj.d5928","journal-title":"BMJ"},{"key":"7435_CR17","doi-asserted-by":"publisher","first-page":"e2019013","DOI":"10.4178\/epih.e2019013","volume":"41","author":"SR Shim","year":"2019","unstructured":"Shim SR et al (2019) Network meta-analysis: application and practice using R software. Epidemiol Health 41:e2019013. https:\/\/doi.org\/10.4178\/epih.e2019013","journal-title":"Epidemiol Health"},{"issue":"12","key":"7435_CR18","doi-asserted-by":"publisher","first-page":"e115065","DOI":"10.1371\/journal.pone.0115065","volume":"9","author":"B Neupane","year":"2014","unstructured":"Neupane B et al (2014) Network meta-analysis using R: a review of currently available automated packages. PLoS\u00a0One 9(12):e115065. https:\/\/doi.org\/10.1371\/journal.pone.0115065","journal-title":"PLoS\u00a0One"},{"issue":"4","key":"7435_CR19","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1200\/JCO.1998.16.4.1310","volume":"16","author":"M Al-Sarraf","year":"1998","unstructured":"Al-Sarraf M et al (1998) Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol 16(4):1310\u20131317. https:\/\/doi.org\/10.1200\/JCO.1998.16.4.1310","journal-title":"J Clin Oncol"},{"issue":"6","key":"7435_CR20","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/S1470-2045(15)70126-9","volume":"16","author":"P Blanchard","year":"2015","unstructured":"Blanchard P et al (2015) Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis. Lancet Oncol 16(6):645\u2013655. https:\/\/doi.org\/10.1016\/S1470-2045(15)70126-9","journal-title":"Lancet Oncol"},{"key":"7435_CR21","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.ejca.2019.07.007","volume":"119","author":"Q Yang","year":"2019","unstructured":"Yang Q et al (2019) Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: long-term results of a phase III multicentre randomised controlled trial. Eur J Cancer 119:87\u201396. https:\/\/doi.org\/10.1016\/j.ejca.2019.07.007","journal-title":"Eur J Cancer"},{"issue":"6","key":"7435_CR22","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1007\/s00280-013-2157-2","volume":"71","author":"YH Zhong","year":"2013","unstructured":"Zhong YH et al (2013) Phase II trial of neoadjuvant docetaxel and cisplatin followed by intensity-modulated radiotherapy with concurrent cisplatin in locally advanced nasopharyngeal carcinoma. Cancer Chemother Pharmacol 71(6):1577\u20131583. https:\/\/doi.org\/10.1007\/s00280-013-2157-2","journal-title":"Cancer Chemother Pharmacol"},{"issue":"16","key":"7435_CR23","doi-asserted-by":"publisher","first-page":"3674","DOI":"10.1002\/cncr.32972","volume":"126","author":"AWM Lee","year":"2020","unstructured":"Lee AWM et al (2020) NPC-0501 trial on the value of changing chemoradiotherapy sequence, replacing 5-fluorouracil with capecitabine, and altering fractionation for patients with advanced nasopharyngeal carcinoma. Cancer 126(16):3674\u20133688. https:\/\/doi.org\/10.1002\/cncr.32972","journal-title":"Cancer"},{"issue":"3","key":"7435_CR24","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1093\/annonc\/mdx770","volume":"29","author":"M Frikha","year":"2018","unstructured":"Frikha M et al (2018) A randomized trial of induction docetaxel-cisplatin-5FU followed by concomitant cisplatin-RT versus concomitant cisplatin-RT in nasopharyngeal carcinoma (GORTEC 2006\u201302). Ann Oncol 29(3):731\u2013736. https:\/\/doi.org\/10.1093\/annonc\/mdx770","journal-title":"Ann Oncol"},{"issue":"8","key":"7435_CR25","doi-asserted-by":"publisher","first-page":"3592","DOI":"10.1002\/cam4.1626","volume":"7","author":"P Gabani","year":"2018","unstructured":"Gabani P et al (2018) Induction chemotherapy in the treatment of nasopharyngeal carcinoma: clinical outcomes and patterns of care. Cancer Med 7(8):3592\u20133603. https:\/\/doi.org\/10.1002\/cam4.1626","journal-title":"Cancer Med"},{"issue":"4","key":"7435_CR26","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1634\/theoncologist.2018-0522","volume":"24","author":"PY OuYang","year":"2019","unstructured":"OuYang PY et al (2019) A pairwise meta-analysis of induction chemotherapy in nasopharyngeal carcinoma. Oncologist 24(4):505\u2013512. https:\/\/doi.org\/10.1634\/theoncologist.2018-0522","journal-title":"Oncologist"},{"issue":"1","key":"7435_CR27","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s40880-019-0385-5","volume":"39","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Sun Y, Ma J (2019) Induction gemcitabine and cisplatin in locoregionally advanced nasopharyngeal carcinoma. Cancer Commun (Lond) 39(1):39. https:\/\/doi.org\/10.1186\/s40880-019-0385-5","journal-title":"Cancer Commun (Lond)"},{"issue":"9","key":"7435_CR28","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1007\/s00432-020-03229-3","volume":"146","author":"J Zang","year":"2020","unstructured":"Zang J et al (2020) Gemcitabine and cisplatin versus docetaxel and cisplatin as induction chemotherapy followed by concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma from non-endemic area of China. J Cancer Res Clin Oncol 146(9):2369\u20132378. https:\/\/doi.org\/10.1007\/s00432-020-03229-3","journal-title":"J Cancer Res Clin Oncol"},{"key":"7435_CR29","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.oraloncology.2019.08.001","volume":"97","author":"J Zhu","year":"2019","unstructured":"Zhu J et al (2019) Comparison of GP and TPF induction chemotherapy for locally advanced nasopharyngeal carcinoma. Oral Oncol 97:37\u201343. https:\/\/doi.org\/10.1016\/j.oraloncology.2019.08.001","journal-title":"Oral Oncol"},{"issue":"1","key":"7435_CR30","doi-asserted-by":"publisher","first-page":"15581","DOI":"10.1038\/s41598-018-33614-5","volume":"8","author":"Z Zeng","year":"2018","unstructured":"Zeng Z et al (2018) Assessment of concurrent chemoradiotherapy plus induction chemotherapy in advanced nasopharyngeal carcinoma: cisplatin, fluorouracil, and docetaxel versus gemcitabine and cisplatin. Sci Rep 8(1):15581. https:\/\/doi.org\/10.1038\/s41598-018-33614-5","journal-title":"Sci Rep"},{"issue":"9","key":"7435_CR31","doi-asserted-by":"publisher","first-page":"3335","DOI":"10.1172\/JCI83871","volume":"125","author":"Y Yang","year":"2015","unstructured":"Yang Y (2015) Cancer immunotherapy: harnessing the immune system to battle cancer. J Clin Investig 125(9):3335\u20133337. https:\/\/doi.org\/10.1172\/JCI83871","journal-title":"J Clin Investig"},{"issue":"10","key":"7435_CR32","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1016\/S1470-2045(18)30495-9","volume":"19","author":"W Fang","year":"2018","unstructured":"Fang W et al (2018) Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials. Lancet Oncol 19(10):1338\u20131350. https:\/\/doi.org\/10.1016\/S1470-2045(18)30495-9","journal-title":"Lancet Oncol"},{"issue":"9","key":"7435_CR33","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1038\/s41591-021-01444-0","volume":"27","author":"HQ Mai","year":"2021","unstructured":"Mai HQ et al (2021) Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial. Nat Med 27(9):1536\u20131543. https:\/\/doi.org\/10.1038\/s41591-021-01444-0","journal-title":"Nat Med"},{"issue":"8","key":"7435_CR34","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1016\/S1470-2045(21)00302-8","volume":"22","author":"Y Yang","year":"2021","unstructured":"Yang Y et al (2021) Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 22(8):1162\u20131174. https:\/\/doi.org\/10.1016\/S1470-2045(21)00302-8","journal-title":"Lancet Oncol"}],"container-title":["European Archives of Oto-Rhino-Laryngology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00405-022-07435-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00405-022-07435-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00405-022-07435-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T12:10:07Z","timestamp":1664367007000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00405-022-07435-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,29]]},"references-count":34,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["7435"],"URL":"https:\/\/doi.org\/10.1007\/s00405-022-07435-2","relation":{},"ISSN":["0937-4477","1434-4726"],"issn-type":[{"value":"0937-4477","type":"print"},{"value":"1434-4726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,29]]},"assertion":[{"value":"28 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All the authors consent the publication of this work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}